title: Update on Exhaled Nitric Oxide in Clinical Practice.
abstract: Asthma is characterized by chronic airway inflammation. Fractional exhaled nitric oxide (Feno) has emerged as a marker of T-helper cell type 2-mediated allergic airway inflammation. Recent studies suggest a role for Feno testing as a point-of-care tool in the management of patients with asthma. This Topics in Practice Management article reviews current coverage and reimbursement issues related to Feno testing and provides an overview of pertinent recent studies.
authors.affiliation: Department of Pulmonary, Critical Care, and Sleep Medicine, Tuality Healthcare, Hillsboro, OR.
authors.forename: Srinivas R
authors.initials: SR
authors.lastname: Mummadi
authors.affiliation: Department of Pulmonary, Critical Care, and Sleep Medicine, Tuality Healthcare, Hillsboro, OR. Electronic address: hahnpy@gmail.com.
authors.forename: Peter Y
authors.initials: PY
authors.lastname: Hahn
mesh_terms: D000280:Administration, Inhalation; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D001249:Asthma / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology; D015415:Biomarkers; D001944:Breath Tests / Q000379:methods*; D006801:Humans; D007249:Inflammation; D019458:Insurance Coverage; D009569:Nitric Oxide / Q000032:analysis* / Q000276:immunology; D000067716:Point-of-Care Testing / Q000191:economics; D012051:Reimbursement Mechanisms; D018418:Th2 Cells / Q000276:immunology
chemical_list: D000305:Adrenal Cortex Hormones; D015415:Biomarkers; D009569:Nitric Oxide
keywords: asthma; nitric oxide